Histologic subtypes of ovarian carcinoma: an overview.
暂无分享,去创建一个
[1] S. Scudder,et al. Clinicopathologic significance of transitional cell carcinoma pattern in nonlocalized ovarian epithelial tumors (stages 2-4). , 1998, American journal of clinical pathology.
[2] D. Cao,et al. Expression of Mesothelin, Fascin, and Prostate Stem Cell Antigen in Primary Ovarian Mucinous Tumors and Their Utility in Differentiating Primary Ovarian Mucinous Tumors From Metastatic Pancreatic Mucinous Carcinomas in the Ovary , 2005, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[3] R. Scully,et al. Benign and borderline clear cell adenofibromas of the ovary , 1985, Cancer.
[4] Joan G. Jones,et al. Differential Expression of WT1 and p53 in Serous and Endometrioid Carcinomas of the Endometrium , 2004, International Journal of Gynecological Pathology.
[5] M. Merino,et al. Loss of heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior. , 2000, Human pathology.
[6] Oscar Lin,et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. , 2003, Gynecologic oncology.
[7] T. Nikaido,et al. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas , 1999, Cancer.
[8] Christopher P Crum,et al. The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.
[9] R. Kurman,et al. Diagnostic Criteria and Behavior of Ovarian Seromucinous (Endocervical-Type Mucinous and Mixed Cell-Type) Tumors: Atypical Proliferative (Borderline) Tumors, Intraepithelial, Microinvasive, and Invasive Carcinomas , 2002, The American journal of surgical pathology.
[10] S. Silverberg. Histopathologic grading of ovarian carcinoma: a review and proposal. , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[11] E. Kohn,et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. , 2004, Human pathology.
[12] W. R. Hart,et al. Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up. , 1998, The American journal of surgical pathology.
[13] H. Tsuda,et al. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. , 2007, Human pathology.
[14] Brigitte M. Ronnett,et al. Primary and Metastatic Mucinous Adenocarcinomas in the Ovaries: Incidence in Routine Practice With a New Approach to Improve Intraoperative Diagnosis , 2003, The American journal of surgical pathology.
[15] D. Bodurka,et al. Undifferentiated Carcinoma of the Endometrium , 2005, The American journal of surgical pathology.
[16] I. Shih,et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.
[17] A. Gown,et al. p16 Expression in Primary Ovarian Mucinous and Endometrioid Tumors and Metastatic Adenocarcinomas in the Ovary: Utility for Identification of Metastatic HPV-Related Endocervical Adenocarcinomas , 2007, The American journal of surgical pathology.
[18] R. Young,et al. Transitional Cell Carcinoma of the Ovary: A Morphologic Study of 100 Cases With Emphasis on Differential Diagnosis , 2004, The American journal of surgical pathology.
[19] M. Leitao,et al. Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion , 2005, Modern Pathology.
[20] B. Czernobilsky,et al. Ovarian endometrioid tumors mimicking sertoli and sertoli‐leydig cell tumors. Sertoliform variant of endometrioid carcinoma , 1982, Cancer.
[21] N. Goldstein,et al. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. , 2002, American journal of clinical pathology.
[22] J. Klijn,et al. Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.
[23] M. Dimopoulos,et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. , 2006, Gynecologic oncology.
[24] T. Jacks,et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer , 2005, Nature Medicine.
[25] I. Jacobs,et al. Histopathologic Features of Genetically Determined Ovarian Cancer , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[26] Rochelle L. Garcia,et al. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. , 2007, Human pathology.
[27] A. Gown,et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases , 2006, Modern Pathology.
[28] R. Young,et al. Endometrioid Neoplasms With Clear Cells: A Report of 21 Cases in Which the Alteration is not of Typical Secretory Type , 2007, The American journal of surgical pathology.
[29] E. Jaffe. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .
[30] B. Werness,et al. Correlation of TP53 mutations and p53 expression in ovarian tumors. , 1998, Cancer genetics and cytogenetics.
[31] X. Matías-Guiu,et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. , 2005, Human pathology.
[32] A. Gown,et al. Ovarian Atypical Proliferative (Borderline) Mucinous Tumors: Gastrointestinal and Seromucinous (Endocervical-Like) Types are Immunophenotypically Distinctive , 2006, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[33] R. Scully,et al. Mucinous Tumors of the Ovary: A Clinicopathologic Study of 196 Borderline Tumors (of Intestinal Type) and Carcinomas, Including an Evaluation of 11 Cases With `Pseudomyxoma Peritonei' , 2000, The American journal of surgical pathology.
[34] R. Scully,et al. Ovarian endometrioid carcinomas resembling sex cord‐stromal tumors: A clinicopathological analysis of 13 cases , 1982, The American journal of surgical pathology.
[35] L. Cope,et al. Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation , 2005, The American journal of surgical pathology.
[36] M. Noguchi,et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. , 2000, Cancer research.
[37] R. Kurman,et al. Immunohistochemical Evidence Supporting the Appendiceal Origin of Pseudomyxoma Peritonei in Women , 1997, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[38] Paul J. L. Zhang,et al. WT1 is Differentially Expressed in Serous, Endometrioid, Clear Cell, and Mucinous Carcinomas of the Peritoneum, Fallopian Tube, Ovary, and Endometrium , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[39] A. Gown,et al. Cytokeratins 7 and 20 in Primary and Secondary Mucinous Tumors of the Ovary: Analysis of Coordinate Immunohistochemical Expression Profiles and Staining Distribution in 179 Cases , 2006, The American journal of surgical pathology.
[40] A. Thor,et al. p53 gene mutations and protein accumulation in human ovarian cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[41] A. Sood,et al. Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary , 2006, Obstetrics and gynecology.
[42] R. Young,et al. Lung Carcinoma Metastatic to the Ovary: A Clinicopathologic Study of 32 Cases Emphasizing Their Morphologic Spectrum and Problems in Differential Diagnosis , 2005, The American journal of surgical pathology.
[43] M. Morgan,et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. , 1996, The New England journal of medicine.
[44] A. Gown,et al. Wilms Tumor Gene Product: Sensitive and Contextually Specific Marker of Serous Carcinomas of Ovarian Surface Epithelial Origin , 2004, Applied immunohistochemistry & molecular morphology : AIMM.
[45] Dianne Miller,et al. Synchronous and Metachronous Endocervical and Ovarian Neoplasms: Evidence Supporting Interpretation of the Ovarian Neoplasms as Metastatic Endocervical Adenocarcinomas Simulating Primary Ovarian Surface Epithelial Neoplasms , 2005, The American journal of surgical pathology.
[46] T. Okai,et al. K-ras mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma , 2004, Medical Electron Microscopy.
[47] Kathleen R. Cho,et al. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. , 2001, Cancer research.
[48] H. Fox,et al. Ovarian clear cell adenofibromatous tumors. Benign, of low malignant potential, and associated with invasive clear cell carcinoma , 1984, Cancer.
[49] R. Kurman,et al. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the Distinction of Metastatic Mucinous Carcinomas in the Ovary From Primary Ovarian Mucinous Tumors: Dpc4 Assists in Identifying Metastatic Pancreatic Carcinomas , 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[50] G. Moreno-Bueno,et al. &bgr;-Catenin Expression Pattern, &bgr;-Catenin Gene Mutations, and Microsatellite Instability in Endometrioid Ovarian Carcinomas and Synchronous Endometrial Carcinomas , 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[51] J. Prat,et al. Serous Borderline Tumors of the Ovary: A Long-Term Follow-Up Study of 137 Cases, Including 18 With a Micropapillary Pattern and 20 With Microinvasion , 2002, The American journal of surgical pathology.
[52] T. Caputo,et al. A Comparative Analysis of 57 Serous Borderline Tumors With and Without a Noninvasive Micropapillary Component , 2002, The American journal of surgical pathology.
[53] T. Colgan. Challenges in the Early Diagnosis and Staging of Fallopian-Tube Carcinomas Associated with BRCA Mutations , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[54] T. Ulbright,et al. Papillary serous carcinoma of the ovary with squamous differentiation. , 1990, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[55] S. Leung,et al. Mixed Ovarian Epithelial Carcinomas With Clear Cell and Serous Components are Variants of High-grade Serous Carcinoma: An Interobserver Correlative and Immunohistochemical Study of 32 Cases , 2008, The American journal of surgical pathology.
[56] R. Young,et al. From Krukenberg to Today: The Ever Present Problems Posed by Metastatic Tumors in the Ovary: Part I. Historical Perspective, General Principles, Mucinous Tumors Including the Krukenberg Tumor , 2006, Advances in anatomic pathology.
[57] J. Kigawa,et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging , 2006, British Journal of Cancer.
[58] A. Malpica,et al. Ovarian Mixed-Epithelial Carcinomas With a Microcystic Pattern and Signet-Ring Cells , 2001, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[59] R. Kurman,et al. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. , 1997, The American journal of surgical pathology.
[60] R. Scully,et al. Ovarian mixed‐epithelial papillary cystadenomas of borderline malignancy of mullerian type: A clinicopathologic analysis , 1988, Cancer.
[61] L. Horn,et al. Serous Carcinoma of the Endometrium with Choriocarcinomatous Differentiation: A Case Report and Review of the Literature Indicate the Existence of 2 Prognostically Relevant Tumor Types , 2006, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[62] R. Broaddus,et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. , 2004, Human pathology.
[63] A. Folpe,et al. Immunoprofile of Ovarian Tumors With Putative Transitional Cell (Urothelial) Differentiation Using Novel Urothelial Markers: Histogenetic and Diagnostic Implications , 2003, The American journal of surgical pathology.
[64] R. Young,et al. The Distinction Between Primary and Metastatic Mucinous Carcinomas of the Ovary: Gross and Histologic Findings in 50 Cases , 2003, The American journal of surgical pathology.
[65] H. Hemmi,et al. Microsatellite status and immunohistochemical features of ovarian clear-cell carcinoma. , 2005, Anticancer research.
[66] Chung-Liang Ho,et al. Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors , 2004, Cancer Research.
[67] H. Moch,et al. Glypican-3 Expression in Primary and Recurrent Ovarian Carcinomas , 2007, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[68] J. Boyd,et al. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. , 2004, Gynecologic oncology.
[69] R. Scully,et al. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis , 1988, Cancer.
[70] R. Kurman,et al. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well‐differentiated carcinoma , 1982, Cancer.
[71] J. Lang,et al. [Clinical characteristics of clear cell carcinoma of the ovary]. , 2002, Zhonghua fu chan ke za zhi.
[72] T. Okai,et al. Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability. , 2004, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[73] I. Konishi,et al. Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas , 2004, Virchows Archiv.
[74] M. Inoue,et al. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. , 1991, The American journal of pathology.
[75] Brigitte M. Ronnett,et al. The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin , 2004, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[76] J. Prat,et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. , 2004, Human pathology.
[77] J. Cain,et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. , 1996, Gynecologic oncology.
[78] A. El‐Naggar,et al. Molecular profile of advanced-stage transitional cell carcinoma of the ovary. , 1997, American journal of obstetrics and gynecology.
[79] A. du Bois,et al. Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. , 2005, Gynecologic oncology.
[80] H. Tsuda,et al. Clear Cell Adenocarcinoma Associated With Clear Cell Adenofibromatous Components: A Subgroup of Ovarian Clear Cell Adenocarcinoma With Distinct Clinicopathologic Characteristics , 2007, The American journal of surgical pathology.
[81] I. Shih,et al. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.
[82] A. Malpica,et al. Micropapillary and Cribriform Patterns in Ovarian Serous Tumors of Low Malignant Potential: A Study of 99 Advanced Stage Cases , 2002, The American journal of surgical pathology.
[83] Tsutomu Ohta,et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. , 2003, The American journal of pathology.
[84] E. Oliva,et al. High frequency of β‐catenin mutations in borderline endometrioid tumours of the ovary , 2006, The Journal of pathology.
[85] Mitsuaki Suzuki,et al. Low Proliferation Activity May Be Associated With Chemoresistance in Clear Cell Carcinoma of the Ovary , 2002, Obstetrics and gynecology.
[86] P. Vyas,et al. Pathology and genetics: Tumours of haematopoietic and lymphoid tissues , 2001 .
[87] Michael T Deavers,et al. Grading Ovarian Serous Carcinoma Using a Two-Tier System , 2004, The American journal of surgical pathology.
[88] Mitsuaki Suzuki,et al. Clinical characteristics of clear cell carcinoma of the ovary , 2000, Cancer.
[89] H. Kajiyama,et al. Long‐term follow‐up and prognostic factor analysis in clear cell adenocarcinoma of the ovary , 2006, Journal of surgical oncology.
[90] K. Cooper,et al. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma , 2006, Journal of surgical oncology.
[91] J. McKenney,et al. Ovarian Serous Tumors of Low Malignant Potential (Borderline Tumors): Outcome-Based Study of 276 Patients With Long-Term (≥5-Year) Follow-Up , 2005, The American journal of surgical pathology.
[92] T. Motoyama,et al. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary , 2006, Modern Pathology.
[93] I. Shih,et al. Diverse tumorigenic pathways in ovarian serous carcinoma. , 2002, The American journal of pathology.
[94] J. Prat,et al. Mucinous Tumors of the Ovary: A Clinicopathologic Analysis of 75 Borderline Tumors (of Intestinal Type) and Carcinomas , 2002, The American journal of surgical pathology.
[95] T. Ulbright,et al. Ovarian Endometrioid Tumors of Low Malignant Potential: A Clinicopathologic Study of 30 Cases With Comparison to Well-Differentiated Endometrioid Adenocarcinoma , 2003, The American journal of surgical pathology.
[96] R. Kurman,et al. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. , 1999, The American journal of surgical pathology.
[97] R. Scully,et al. Endometrioid Carcinoma of the Ovary with a Prominent Spindle‐cell Component, a Source of Diagnostic Confusion A Report of 14 Cases , 1995, The American journal of surgical pathology.
[98] M. Hendrickson,et al. Proposed Criteria for the Diagnosis of Well‐Differentiated Endometrial Carcinoma: A Diagnostic Test for Myoinvasion , 1995, The American journal of surgical pathology.
[99] M. Sherman,et al. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. , 1996, The American journal of surgical pathology.
[100] M. Waldstrøm,et al. Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. , 2005, Archives of pathology & laboratory medicine.
[101] R. Scully,et al. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. , 1999, The American journal of surgical pathology.
[102] D. Gershenson,et al. Ovarian carcinomas with transitional cell carcinoma pattern. , 1990, American journal of clinical pathology.
[103] R. Caduff,et al. Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. , 1998, The American journal of surgical pathology.
[104] M. Birrer,et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. , 1993, Cancer research.
[105] X. Matías-Guiu,et al. Microsatellite instability, MLH‐1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors , 2001, Cancer.
[106] Kathleen R. Cho,et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. , 2007, Cancer cell.
[107] Ximing J. Yang,et al. Human Kidney Injury Molecule-1 (hKIM-1): A Useful Immunohistochemical Marker for Diagnosing Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma , 2007, The American journal of surgical pathology.
[108] E. Venkatraman,et al. Clinicopathologic Analysis of Early-stage Sporadic Ovarian Carcinoma , 2004, The American journal of surgical pathology.
[109] M. Sherman,et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. , 2004, Human pathology.
[110] A. Malpica,et al. Differential Expression of WT-1 in Serous Carcinomas in the Peritoneum With or Without Associated Serous Carcinoma in Endometrial Polyps , 2005, The American journal of surgical pathology.
[111] I. Konishi,et al. Immunohistochemical Detection of the Wilms' Tumor Gene (WT1) in Epithelial Ovarian Tumors , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[112] Mitsuaki Suzuki,et al. Screening of BRCA1 Mutation Using Immunohistochemical Staining with C‐Terminal and N‐Terminal Antibodies in Familial Ovarian Cancers , 2000, Japanese journal of cancer research : Gann.
[113] R. Kurman,et al. A Clinicopathologic Analysis of Atypical Proliferative (Borderline) Tumors and Well-Differentiated Endometrioid Adenocarcinomas of the Ovary , 2000, The American journal of surgical pathology.
[114] E. Oliva,et al. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma , 2005, Modern Pathology.
[115] N. Ordóñez,et al. Transitional cell carcinoma in high‐grade high‐stage ovarian carcinoma. An indicator of favorable response to chemotherapy , 1989, Cancer.
[116] Mukesh Verma,et al. WT1 and WT1‐AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma , 2005, Cancer.
[117] R. Kurman,et al. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. , 1996, The American journal of surgical pathology.
[118] T. Colgan,et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. , 2006, Gynecologic oncology.
[119] P. Radice,et al. Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions: Report of 6 Cases and Review of the Literature , 2006, The American journal of surgical pathology.
[120] L. Mazzucchelli,et al. Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: a possible link to endometrioid adenocarcinoma , 2006, Modern Pathology.